Scott M. Rocklage is the founding partner of 5AM Ventures, a leading venture capital firm. He has over 30 years of experience in healthcare management, and helped get three new drug applications approved by the FDA. He has held several executive positions throughout his career including CEO and Chairman of Cubist Pharmaceuticals, Executive Chairman of Ilypsa, Semprus and Miikana, CEO and President of Nycomed Salutar and has serves as Board Chairman of Cidara, Rennovia and Kinestral. Scott Rocklage gradudated from the University of California, Berkeley with a Bachelor’s in Chemistry, and earned his PhD from the Massachusetts Institute of Technology.
Myotonic dystrophy type I (or DM1) is the number one cause of muscular dystrophy. The company Expansion Therapeutics, has been trying to raise funds to help fight this genetic disorder. Scott Rocklage’s company 5AM Ventures, is helping Expansion Therapeutics by taking the lead in the financing of this research. Molecules that are converted into proteins from DNA are called RNAs. Sometimes, RNAs can reach toxic levels in the cells and cause the hormonal system, gastrointestinal system and the heart become ineffective. Currently there is no cure or effective treatment for DM1.
Scott Rocklage is the co-inventor of over 30 U.S. Patents and has written over 100 publications. 5AM Ventures focuses on life science companies that are using cutting edge breakthroughs when developing healthcare solutions. 5AM Ventures only employs a staff of individuals with strong skills in business management, finance, legal, and scientific and medical backgrounds. Under Scott’s leadership, 5AM Ventures has a role in all aspects of business operations including serving strategists, board members and operations managers.
To learn more, visit http://5amventures.com/team/scott-m-rocklage-phd/.